Palivizumab is an FDA-approved monoclonal antibody for preventing severe respiratory syncytial virus (RSV) infections in high-risk children. However, its real-world safety profile, particularly beyond clinical trial populations, remains incompletely characterized. This study aimed to systematically analyze adverse events (AEs) associated with palivizumab using two decades of data from the FDA Adverse Event Reporting System (FA...